Drugs / Nicotinamide riboside
Nicotinamide riboside
also known as
Niagen · NiagenPlus · Nicotinamide ribonucleoside · nicotinamide riboside chloride · NRCl · Ribosylnicotinamide · TRU NIAGEN
Trials 31 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04430517 | Mar 2022 → Apr 2026 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Mclean Hospital | Completed | No outcome recorded |
| Phase 0 | NCT04528004 | Sep 2020 → Nov 2024 overdue | advanced heart failure, metabolic disease, systolic heart failure | University of Washington | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04332341 | May 2020 → Sep 2026 expected | disease related to hematopoietic stem cell transplant | Case Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT07251608 | Oct 2025 → Feb 2026 overdue | — | ChromaDex, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06280482 | Mar 2024 → Jul 2027 expected | multisystemic smooth muscle dysfunction syndrome | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 1 | NCT06214468 | Jan 2024 → Apr 2025 | poisoning | University of South Alabama | Completed | No outcome recorded |
| Phase 1 | NCT04994561 | Jun 2022 → Dec 2023 | — | Vitality in Aging Research Group, Inc. | Withdrawn | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06534944 | Feb 2023 → Jul 2024 | peripheral arterial disease | University of Oklahoma | Completed | No outcome recorded |
| Phase 1/2 | NCT04110028 | Oct 2019 → Dec 2022 | — | Oslo University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03482167 | Mar 2019 → Jan 2024 | cognitive impairment with or without cerebellar ataxia | University of Delaware | Completed | No outcome recorded |
| Phase 1/2 | NCT03685253 | Jan 2019 → May 2022 | diabetic polyneuropathy | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 1/2 | NCT03423342 | May 2016 → Apr 2019 | systolic heart failure | University of Washington | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT07579429 | May 2026 → Dec 2029 expected | clonal hematopoiesis of indeterminate potential, myelodysplastic syndrome | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT06567717 | Nov 2025 → Jan 2027 expected | idiopathic pulmonary fibrosis | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05590468 | May 2023 → Nov 2026 expected | pure mitochondrial myopathy | Ralitza Gavrilova | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04818216 | Jun → Dec 2021 | COVID-19, acute kidney injury | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 2 | NCT03912220 | Sep 2020 → May 2023 | neuropathy, small fiber | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT04112641 | Feb 2020 → Jun 2026 overdue | chemotherapy-induced neuropathy | Donna Hammond, PhD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04044131 | Dec 2019 → Mar 2021 | Alzheimer disease, Parkinson disease | Istanbul Medipol University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04040959 | Nov 2019 → Jul 2026 overdue | chronic kidney disease, hypertensive disorder | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03642990 | Nov 2019 → Aug 2021 | breast cancer, chemotherapy-induced neuropathy, endometrial cancer, head and neck cancer | Donna Hammond, PhD | Terminated | No outcome recorded |
| Phase 2 | NCT04330326 | Jul 2019 → Jul 2020 | NAFLD1 | ScandiBio Therapeutics AB | Completed | No outcome recorded |
| Phase 2 | NCT04870866 | Jun 2019 → Sep 2024 overdue | ataxia telangiectasia | University Hospital, Akershus | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03821623 | May 2019 → Jun 2025 overdue | hypertensive disorder | Douglas Seals | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04573153 | Sep 2020 → May 2022 | COVID-19 | ScandiBio Therapeutics AB | Terminated | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05483465 | May 2023 → Jun 2027 expected | — | University of Oklahoma | Recruiting | No outcome recorded |
| Phase 4 | NCT04809974 | Aug 2021 → Oct 2023 | COVID-19, cognitive disorder, post-infectious disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03151707 | Oct 2017 → Sep 2022 | — | Mclean Hospital | Terminated | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07563322 | Apr 2026 → Apr 2027 expected | pulmonary hypertension | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| — | NCT06324877 | May 2024 → Oct 2025 | ataxia telangiectasia | The University of Queensland | Unknown | No outcome recorded |
| — | NCT04841499 | Apr → Jul 2021 | — | University of South Alabama | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04112043 Comparator | Jul 2020 → May 2023 | hypertensive disorder | University of Florida | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04913805 Comparator | Oct 2021 → May 2027 expected | diastolic heart failure | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 2 | NCT04342975 Comparator | Dec 2020 → Mar 2024 | acute kidney injury | Mayo Clinic | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03743636 Comparator | Oct 2018 → May 2023 | peripheral arterial disease | Northwestern University | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nicotinamide Riboside | “Second, the investigators will include nicotinamide riboside, precursor of nicotinamide adenine dinucleotide (NAD+) to boost the level of hepatic β-oxidation of fatty acids in...” NCT04330326 ↗31“This study will provide insight into whether a nutritional supplement, nicotinamide riboside (NR), improves memory and brain blood flow in older adults with low memory abilities.” NCT03482167 ↗ “Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).” NCT04573153 ↗ “subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol” NCT04994561 ↗ “Raising NAD+ levels with the NAD+ precursor, nicotinamide riboside (NR), may represent a novel HF treatment.” PMID 36644285 ↗ Sep 2022 “Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.” NCT04044131 ↗ “Subjects will receive vitamin B3 derivative Nicotinamide Riboside (NR) daily for 12 months” NCT05590468 ↗ “an injectable form of nicotinamide riboside (NR)” NCT07251608 ↗ “Nicotinamide Riboside (NR)” NCT07563322 ↗ |
| Known as | Niagen | “Nicotinamide riboside, a dietary supplement available over the counter under the name NIAGEN®, (ChromaDex Inc) is an exogenous NAD+ precursor that reverses age-related arterial...” NCT03821623 ↗4“oral nicotinamide riboside (500 mg capsules 2x/day; NIAGEN®; ChromaDex Inc.) for 3 months vs. placebo” NCT04040959 ↗ “Nicotinamide ribonuceloside (NR), sold under the trade name Niagen™” NCT04870866 ↗ |
| Known as | NiagenPlus | “The goal of this study is to learn about the safety of Niagen®Plus, an injectable form of nicotinamide riboside (NR)” NCT07251608 ↗ |
| Known as | Nicotinamide ribonucleoside | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04870866 ↗ |
| Known as | nicotinamide riboside chloride | “Niagen®Plus (nicotinamide riboside chloride, NRCl)” NCT07251608 ↗ |
| Known as | NRCl | “Niagen®Plus (nicotinamide riboside chloride, NRCl)” NCT07251608 ↗ |
| Known as | Ribosylnicotinamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL438497 ↗ |
| Known as | TRU NIAGEN | “Nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.” NCT04332341 ↗ |
| Action | Restore | “restoration of Nicotinamide Adenine Dinucleotide (NAD) levels with Nicotinamide Riboside (NR)” NCT05483465 ↗ |
| Modality | Small molecule | — CHEMBL438497 ↗ |
| Route | Oral | “Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally.” NCT03423342 ↗ |